Article R. 22-10-23 of the French Industrial Code
Market : Euronext Paris
ISIN code / Mnemo : FR0013233012 / IVA
Site : www.inventivapharma.com
| Variety of Shares Excellent
Whole voting rights,
Whole voting rights,
|December 19, 2022||42 134 169||55 144 801||55 029 868|
(1) The whole variety of gross (or “theoretical”) voting rights is used as the idea for calculating threshold crossings. In accordance with Article 223-11 of the AMF Normal Laws, this quantity is calculated on the idea of all shares to which voting rights are connected, together with these for which voting rights have been suspended.
(2) The whole variety of internet (or “exercisable at a Shareholders’ Assembly”) voting rights is calculated with out taking into consideration shares for which voting rights have been suspended, i.e. treasury shares (together with shares bought below the liquidity contract). It’s launched with a purpose to be sure that the general public is correctly knowledgeable.
Inventiva is a clinical-stage biopharmaceutical firm centered on the analysis and growth of oral small molecule therapies for the remedy of sufferers with NASH, mucopolysaccharidoses (MPS) and different illnesses with important unmet medical wants. The Firm advantages from a robust experience and expertise within the area of compounds concentrating on nuclear receptors, transcription components and epigenetic modulation. Inventiva is at present advancing one medical candidate, has a pipeline of two preclinical packages and continues to discover different growth alternatives so as to add to its pipeline.
Inventiva’s lead product candidate, lanifibranor, is at present in a pivotal Part III medical trial, NATiV3, for the remedy of grownup sufferers with NASH, a standard and progressive power liver illness for which there are at present no permitted therapies. In 2020, Inventiva reported constructive outcomes from its Part IIb medical trial evaluating lanifibranor for the remedy of sufferers with NASH and acquired Breakthrough Remedy and Quick Observe standing from the U.S. Meals and Drug Administration (“FDA”) for lanifibranor within the remedy of NASH.
Inventiva’s pipeline additionally consists of odiparcil, a drug candidate for the remedy of grownup MPS VI sufferers. As a part of Inventiva’s choice to focus medical efforts on the event of lanifibranor, it suspended its medical efforts referring to odiparcil and is reviewing accessible choices with respect to its potential additional growth. Inventiva is within the course of of choosing an oncology growth candidate for its Hippo signaling pathway program.
The Firm has a scientific workforce of roughly 80 individuals with deep experience within the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and medical growth. It owns an in depth library of roughly 240,000 pharmacologically related molecules, roughly 60% of that are proprietary, in addition to a wholly-owned analysis and growth facility.
Inventiva is a public firm listed on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq International Market in the US (ticker: IVA). www.inventivapharma.com.
This press launch comprises “forward-looking statements” throughout the that means of the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. All statements, aside from statements of historic info, included on this press launch are forward-looking statements. These statements embrace, however aren’t restricted to, Inventiva’s pipeline and preclinical and medical growth plans, future actions, expectations, plans, progress and prospects of Inventiva and its product candidates. Sure of those statements, forecasts and estimates could be acknowledged by means of phrases similar to, with out limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “might”, “will”, “would”, “may”, “may”, “ought to”, and “proceed” and related expressions. Such statements aren’t historic info however quite are statements of future expectations and different forward-looking statements which are based mostly on administration’s beliefs. These statements replicate such views and assumptions prevailing as of the date of the statements and contain identified and unknown dangers and uncertainties that might trigger future outcomes, efficiency or future occasions to vary materially from these expressed or implied in such statements. Future occasions are tough to foretell and should rely upon components which are past Inventiva’s management. There could be no ensures with respect to pipeline product candidates that the medical trial outcomes might be accessible on their anticipated timeline, that future medical trials might be initiated as anticipated, that product candidates will obtain the required regulatory approvals. Precise outcomes might develop into materially totally different from the anticipated future outcomes, efficiency or achievements expressed or implied by such statements, forecasts and estimates, resulting from quite a lot of components, together with that Inventiva is a clinical-stage firm with no permitted merchandise and no historic product revenues, Inventiva has incurred important losses since inception, Inventiva has a restricted working historical past and has by no means generated any income from product gross sales, Inventiva would require further capital to finance its operations, Inventiva’s future success depends on the profitable medical growth, regulatory approval and subsequent commercialization of present and any future product candidates, preclinical research or earlier medical trials aren’t essentially predictive of future outcomes and the outcomes of Inventiva’s medical trials might not help Inventiva’s product candidate claims, Inventiva might encounter substantial delays in its medical trials or Inventiva might fail to reveal security and efficacy to the satisfaction of relevant regulatory authorities, enrolment and retention of sufferers in medical trials is an costly and time-consuming course of and might be made harder or rendered not possible by a number of components outdoors Inventiva’s management, Inventiva’s product candidates might trigger adversarial drug reactions or produce other properties that might delay or forestall their regulatory approval, or restrict their business potential, Inventiva faces substantial competitors and Inventiva’s enterprise, and preclinical research and medical growth packages and timelines, its monetary situation and outcomes of operations might be materially and adversely affected by the present COVID-19 pandemic and geopolitical occasions, such because the battle between Russia and Ukraine, associated sanctions and associated impacts and potential impacts on the initiation, enrolment and completion of Inventiva’s medical trials on anticipated timelines and macroeconomic situations, together with world inflation and unsure monetary markets or in any respect. Given these dangers and uncertainties, no representations are made as to the accuracy or equity of such forward-looking statements, forecasts and estimates. Moreover, forward-looking statements, forecasts and estimates solely communicate as of the date of this press launch. Readers are cautioned to not place undue reliance on any of those forward-looking statements.
Please check with the Common Registration Doc for the yr ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022, the Annual Report on Kind 20-F for the yr ended December 31, 2021 filed with the Securities and Change Fee on March 11, 2022 and the monetary report for the primary half of 2022 filed with the Securities and Change Fee on September 22, 2022 for extra info in relation to such components, dangers and uncertainties.
All info on this press launch is as of the date of the discharge. Besides as required by regulation, Inventiva has no intention and is below no obligation to replace or overview the forward-looking statements referred to above.
- Inventiva – PR – variety of shares and voting rights as at 19 December 2022 – EN – 01 03 2023